Many biotech startups sell themselves for 8-9 figures before their drugs or therapies reach full market maturity, so that they transfer remaining risks to larger pharma companies. If we quantify the post acquisition capital spend by the big pharma then we can get a picture for what kind of follow on investment market is available.